A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.
Also called NCT03082508
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 240 participants
- Sponsor
- LoneStar Heart, Inc.
- Registry
-
NCT03082508
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT03082508. Randomized; single masking; primary purpose treatment. Start 2017-08 (anticipated); primary completion 2020-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure
- Acronym
- AUGMENT-HFII
- Condition
- Heart Failure
- Condition
- Dilated Cardiomyopathy
- Intervention (Device)
- Algisyl
- Intervention (Drug)
- Standard Medical Therapy
- Lead sponsor
- LoneStar Heart, Inc.
Record details
- Record id
cardio:ct-nct03082508- Content hash
ff738b5c925c0443d7afef5d1b39b0efa44600f75080db413462332bc5247302